Special Issue

Antibody Response Studies on SARS-CoV-2 Vaccine

Message from the Guest Editor

Since the beginning of the COVID-19 pandemic many anti-SARS-CoV-2 vaccine platforms have been developed and used. Anti-SARS-CoV-2 vaccines have significantly reduced the morbidity and mortality associated with this viral infection. Unfortunately, a short-term decline in antibody titer and the emergence of new variants of concern appear to reduce vaccine efficacy and have re-exposed the vaccinated population to COVID-19. Today, there are many data regarding anti-SARS-CoV-2 vaccination in the literature, but many questions remain among them:

- What are the long-term kinetics of antibody titer?
- What is the best vaccination schedule to optimize the immune response?
- Can we define a neutralizing antibody threshold or a protective antibody titer to guide vaccine strategy?
- What strategies should be adopted in immunocompromised patients in order to improve the vaccine response?
- What is the effectiveness of new vaccines, such as recombinant protein vaccines or intranasal vaccines?
- What are the short- and long-term vaccine antibody responses in children?

Guest Editor

Dr. Ilies Benotmane

1. Department of Nephrology and Transplantation, Strasbourg University Hospital, 67200 Strasbourg, France
2. INSERM UMR-S 1109 LabEx TRANSPLANTEX, Strasbourg University, 67000 Strasbourg, France

Deadline for manuscript submissions

closed (15 August 2022)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/112150

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI